Nanoparticle News and Research RSS Feed - Nanoparticle News and Research

In nanotechnology, a particle is defined as a small object that behaves as a whole unit in terms of its transport and properties. It is further classified according to size: in terms of diameter, fine particles cover a range between 100 and 2500 nanometers, while ultrafine particles, on the other hand, are sized between 1 and 100 nanometers.
New approach to imaging metastatic tumors

New approach to imaging metastatic tumors

Bioluminescence, nanoparticles, gene manipulation - these sound like the ideas of a science fiction writer, but, in fact, they are components of an exciting new approach to imaging local and metastatic tumors. [More]
Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Immune Pharmaceuticals Inc. announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC). [More]
Researchers infuse antibody-studded iron nanoparticles into bloodstream to treat heart attack damage

Researchers infuse antibody-studded iron nanoparticles into bloodstream to treat heart attack damage

Researchers at the Cedars-Sinai Heart Institute infused antibody-studded iron nanoparticles into the bloodstream to treat heart attack damage. [More]
Combination miRNA therapy offers promising therapeutic avenue for non-small-cell lung cancer

Combination miRNA therapy offers promising therapeutic avenue for non-small-cell lung cancer

Micro RNAs (miRNA) have recently emerged as key therapeutic agents against cancers and are actively being evaluated in pre-clinical models of various cancers as well as in human clinical trials. [More]
Treating wet AMD with gold nanoparticles: an interview with Jim Taylor, CEO, Oraya Therapeutics

Treating wet AMD with gold nanoparticles: an interview with Jim Taylor, CEO, Oraya Therapeutics

Wet AMD is characterized by abnormal growth of blood vessels in the macula (the area of the eye containing vision-enabling photoreceptors), and is responsible for the vast majority of severe vision loss in the industrialized world. [More]
Versatile nanoparticles offer wide variety of diagnostic and therapeutic applications

Versatile nanoparticles offer wide variety of diagnostic and therapeutic applications

Kit Lam and colleagues from UC Davis and other institutions have created dynamic nanoparticles (NPs) that could provide an arsenal of applications to diagnose and treat cancer. [More]
Researchers made important step towards creating medical nanorobots

Researchers made important step towards creating medical nanorobots

Researchers from the Institute of General Physics of the Russian Academy of Sciences, the Institute of Bioorganic Chemistry of the Russian Academy of Sciences and MIPT have made an important step towards creating medical nanorobots. [More]
Research offers promise for personalized RNA combination therapies to treat lung cancer

Research offers promise for personalized RNA combination therapies to treat lung cancer

Small RNA molecules, including microRNAs (miRNAs) and small interfering RNAs (siRNAs), offer tremendous potential for new therapeutic agents to inhibit cancer cell growth. However, delivering these small RNAs to solid tumors remains a significant challenge, as the RNAs must target the correct cells and avoid being broken down by enzymes in the body. [More]
Bee, snake, scorpion venom could form basis of new generation of cancer-fighting drugs

Bee, snake, scorpion venom could form basis of new generation of cancer-fighting drugs

Bee, snake or scorpion venom could form the basis of a new generation of cancer-fighting drugs, scientists will report here today. [More]
Global therapeutic market for BBB technologies expected to grow at 64.9% CAGR over 2014-2019

Global therapeutic market for BBB technologies expected to grow at 64.9% CAGR over 2014-2019

Reportlinker.com announces that a new market research report is available in its catalogue: Blood-Brain Barrier Technologies and Global Markets. [More]
Oncothyreon acquires Alpine Biosciences to enable targeted delivery of multiple therapeutic agents

Oncothyreon acquires Alpine Biosciences to enable targeted delivery of multiple therapeutic agents

Oncothyreon Inc., a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it has acquired Alpine Biosciences, Inc., of Seattle, Washington, a privately held biotechnology company developing protocells, a nanoparticle platform technology designed to enable the targeted delivery of multiple therapeutic agents, including nucleic acids, proteins, peptides and small molecules. [More]
Researchers exploring ways to stimulate patients' immune system to attack tumors

Researchers exploring ways to stimulate patients' immune system to attack tumors

Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center are exploring ways to wake up the immune system so it recognizes and attacks invading cancer cells. Tumors protect themselves by tricking the immune system into accepting everything as normal, even while cancer cells are dividing and spreading. [More]
Malvern acquires MicroCal business and Affinity Biosensors' Archimedes product

Malvern acquires MicroCal business and Affinity Biosensors' Archimedes product

Malvern Instruments Ltd (Malvern, UK) has today announced that it has completed the acquisition of MicroCal from GE Healthcare Life Sciences and has also purchased the Archimedes particle characterization system from Affinity Biosensors LLC (Santa Barbara, CA). [More]
Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Lyfebulb, the International Pemphigus Pemphigoid Foundation (IPPF) and Immune Pharmaceuticals Inc., announced a collaboration to increase awareness of unmet needs in treating bullous pemphigoid last night at an event attended by more than sixty patients, physicians, scientists and other interested parties. [More]
Tiny gold particles can make cell membranes deliver drugs directly to target cells

Tiny gold particles can make cell membranes deliver drugs directly to target cells

A special class of tiny gold particles can easily slip through cell membranes, making them good candidates to deliver drugs directly to target cells. [More]
New self-assembling nanoparticle helps doctors diagnose cancer earlier

New self-assembling nanoparticle helps doctors diagnose cancer earlier

Scientists have designed a new self-assembling nanoparticle that targets tumours, to help doctors diagnose cancer earlier. [More]
Portable, microchip-based test for diagnosing type-1 diabetes

Portable, microchip-based test for diagnosing type-1 diabetes

An inexpensive, portable, microchip-based test for diagnosing type-1 diabetes could improve patient care worldwide and help researchers better understand the disease, according to the device's inventors at the Stanford University School of Medicine. [More]

Wyatt Technology highlights protein-protein interactions study investigated by dynamic light scattering

Wyatt Technology Corporation, the world leader in absolute macromolecular characterization instrumentation, is pleased to highlight a study recently authored by Martin Skov Neergaard from the Faculty of Health and Medical Sciences at the University of Copenhagen, “Protein-Protein Interactions Investigated by DLS: Determination at High and Low Protein Concentration.” [More]
CNIO researchers identify over 40 genes that predict aggressiveness of melanoma

CNIO researchers identify over 40 genes that predict aggressiveness of melanoma

Researchers from the Spanish National Cancer Research Centre have discovered more than 40 genes that predict the level of aggressiveness of melanoma and that distinguish it from other cancers with a poor prognosis. The discovery, published in Cancer Cell, will help to identify unique aspects of melanoma that could contribute to determine the risk of developing metastasis in patients with this disease. [More]
EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor. [More]